الفهرس Only 14 pages are availabe for public view
 |  | from | 256 |  |  |
| | | from | 256 | | |
Abstract
Since the first application of percutaneous transluminal coronary angioplasty (PTCA) in humans in 1977, catheter-based revascularization has exhibited tremendous growth. The indications have been expanded; innovative technologies emerged; knowledge about the pathophysiology of tissue reactions increased; and new frontiers in pharmaceutical and molecular biology research chartered.
The rapid evolution of stent design, deployment approaches, and adjunctive therapy have led to changes in clinical practice patterns and has broadened the scope of patients that can be approached by PCI beyond those that could be safely treated by PTCA alone.